Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorWick, Antje
dc.contributor.authorDesjardins, Annick
dc.contributor.authorSuárez Rodríguez, Cristina
dc.contributor.authorForsyth, Peter
dc.contributor.authorGueorguieva, Ivelina
dc.contributor.authorBurkholder, Tiana
dc.contributor.authorRodon Ahnert, Jordi
dc.date.accessioned2021-10-26T07:19:31Z
dc.date.available2021-10-26T07:19:31Z
dc.date.issued2020-10
dc.identifier.citationWick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest New Drugs. 2020 Oct;38:1570–1579.
dc.identifier.issn1573-0646
dc.identifier.urihttps://hdl.handle.net/11351/6463
dc.descriptionBiomarcadors; Glioblastoma; Radioqimioteràpia
dc.description.sponsorshipOpen Access funding provided by Projekt DEAL. This trial was funded by Eli Lilly and Company.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesInvestigational New Drugs;38
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectGliomes
dc.subjectCervell - Càncer - Quimioteràpia
dc.subjectCervell - Càncer - Radioteràpia
dc.subject.meshGlioma
dc.subject.meshChemoradiotherapy
dc.titlePhase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10637-020-00910-9
dc.subject.decsglioma
dc.subject.decsquimiorradioterapia
dc.relation.publishversionhttps://doi.org/10.1007/s10637-020-00910-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Wick A] Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. [Desjardins A] The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, NC, USA. [Suarez C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Forsyth P] H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. [Gueorguieva I] Eli Lilly and Company, Erl Wood, UK 6 Eli Lilly and Company, Indianapolis, IN, USA. [Burkholder T] Eli Lilly and Company, Indianapolis, IN, USA. [Rodon J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, TX, USA
dc.identifier.pmid32140889
dc.identifier.wos000518298200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple